A fast-acting psychedelic from plants and toad venom that briefly dissolves the sense of self. A single supervised session has shown rapid relief of hard-to-treat depression and lasting mood lifts, but evidence is small and early, serious risks exist, and it remains illegal in most places outside research. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Blood pressure | ~110–125 / 70–80 mmHg | Screens cardiovascular risk before transient BP surge |
| Resting heart rate | 50–70 bpm | Baseline for the acute heart-rate increase |
| ECG (12-lead) | Normal rhythm, normal QTc (<450 ms men / <460 ms women) | Detects arrhythmia/QT risk before serotonergic/sympathetic load |
| Psychiatric screen (PHQ-9 / GAD-7) | No active psychosis/mania; depression/anxiety scores tracked over time | Establishes baseline severity and excludes high-risk individuals |
| Medication/supplement review | No MAOIs or serotonergic agents active | Prevents serotonin syndrome and prolonged effects |
| CYP2D6 genotype (optional) | Not poor/ultrarapid metabolizer (interpretive) | Anticipates altered exposure to drug and active metabolite |
Cadence: Baseline once before the session; continuous vital-sign and psychological monitoring during the acute experience; follow-up at ~1 week and ~4 weeks, then periodically (e.g., every 1–3 months)